



Corrigendum: Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction

Michelle L. Pleet^{1†}, Allison Mathiesen^{2†}, Catherine DeMarino¹, Yao A. Akpamagbo¹, Robert A. Barclay¹, Angela Schwab¹, Sergey Iordanskiy³, Gavin C. Sampey^{1,4}, Benjamin Lepene⁵, Philipp A. Ilinykh⁶, Alexander Bukreyev^{6,7,8}, Sergei Nekhai⁹, M. Javad Aman¹⁰ and Fatah Kashanchi^{1*}

¹ Laboratory of Molecular Virology, School of Systems Biology, George Mason University, Manassas, VA, USA, ² Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, VA, USA, ³ Department of Microbiology, Immunology and Tropical Medicine, Research Center for Neglected Diseases of Poverty, George Washington University School of Medicine and Health Sciences, Washington, DC, USA, ⁴ Department of Medicine, University of North Carolina HIV Cure Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA, ⁵ Ceres Nanosciences Inc., Manassas, VA, USA, ⁶ Departments of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, USA, ⁷ Microbiology and Immunology, University of Texas Medical Branch at Galveston, TX, USA, ⁸ Galveston National Laboratory, University of Texas Medical Branch at Galveston, TX, USA, ⁹ Department of Medicine, Center for Sickle Cell Disease, Howard University, Washington, DC, USA, ¹⁰ Integrated BioTherapeutics, Inc., Gaithersburg, MD, USA

Keywords: Ebola virus, EBOV, VP40, VLP, exosomes, ESCRT, microRNA, apoptosis

A corrigendum on

OPEN ACCESS

Edited and reviewed by:

Thomas Dandekar, Universität Würzburg, Germany

> *Correspondence: Fatah Kashanchi fkashanc@gmu.edu

[†]These authors have contributed equally to this work.

Specialty section:

This article was submitted to Infectious Diseases, a section of the journal Frontiers in Microbiology

Received: 17 January 2018 Accepted: 23 March 2018 Published: 17 April 2018

Citation:

Pleet ML, Mathiesen A, DeMarino C, Akpamagbo YA, Barclay RA, Schwab A, Iordanskiy S, Sampey GC, Lepene B, Ilinykh PA, Bukreyev A, Nekhai S, Aman MJ and Kashanchi F (2018) Corrigendum: Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction. Front. Microbiol. 9:692. doi: 10.3389/fmicb.2018.00692

Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction

by Pleet, M. L., Mathiesen, A., DeMarino, C., Akpamagbo, Y. A., Barclay, R. A., Schwab, A., et al. (2016). Front. Microbiol. 7:1765. doi: 10.3389/fmicb.2016.01765

In the original publication, Philipp A. Ilinykh and Alexander Bukreyev were not included as authors. The omission of these authors was a miscommunication among proteomics colleagues.

Secondly, there should be a change to Materials and Methods section. In the subsection "Identification of Potential Phosphorylation Sites in VP40 Protein," in the first paragraph, the first sentence should read as follows: "Mass spectra for VP40 was obtained for this manuscript as previously described in our analysis of VP30 from EBOV virions (Ilinykh et al., 2014). Proteomics data for VP40 had not been previously published."

For the third amendment, proteomics data on EBOV virions were mentioned as published whereas these data were not yet published. A correction should be made to Results section. In the sub-section "Ebola VP40 is Phosphorylated by Cyclin-Dependent Kinase 2," in the first paragraph, the sentence should read as follows: "Using our mass spectrometry data of EBOV virions we found Ser-233, Thr-272, Thr-277, and Ser-278 to be potentially phosphorylated (Figures 4A,B). The whole phosphoproteomic analysis of EBOV is ongoing and will be published elsewhere (data not shown)."

The authors apologize and state that these corrections do not change the scientific conclusions of the article in any way.

The original article has been updated.

AUTHOR CONTRIBUTIONS

MP and AM contributed equally to generation of data and writing of the manuscript. CD and AS contributed to some manuscript writing and experimental procedures, especially Figure 7. YA and RB contributed to ultracentrifugation and isolation of exosomes, as well as AchE assays.

SI and GS contributed to plasmid design and purification, transfections and selection of clones. BL contributed nanoparticles. SN performed proteomic analyses of EBOV VP40 for Figure 4 in conjunction with PI and AB. MA provided various reagents and FK contributed to the overall direction and coordination of the project, as well as experimental design, quantitative analyses, and data interpretation.

REFERENCES

Ilinykh, P. A., Tigabu, B., Ivanov, A., Ammosova, T., Obukhov, Y., Garron, T., et al. (2014). Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription. *J. Biol. Chem.* 289, 22723–22738. doi: 10.1074/jbc.M114.575050

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Pleet, Mathiesen, DeMarino, Akpamagbo, Barclay, Schwab, Iordanskiy, Sampey, Lepene, Ilinykh, Bukreyev, Nekhai, Aman and Kashanchi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.